The β-cell effect of verapamil-based treatment in patients with type 2 diabetes: a systematic review
- 26 Downloads
The possibility that verapamil has new beneficial effects in diabetic patients in terms of an improvement in glycometabolic control has been put forward recently in several studies. However, to date the issue is still under debate. We conducted the first systematic review examining the impact of verapamil-based treatment on glycometabolic outcomes, in type 2 diabetes (T2D) patients.
We searched the PubMed, MEDLINE, Embase, Cochrane and ClinicalTrials.gov up to 9 October 2018, for all studies evaluating whether verapamil-based treatment is associated with changes in glycated haemoglobin (HbA1c), fasting plasma glucose levels, glucose and C-peptide areas from baseline in humans, without restrictions for study type.
Plasma glucose levels were lowered significantly by verapamil-based treatment in patients with T2D (mean change − 13 ± 5.29; P = 0.049); HbA1c values were instead not affected by the drug (mean change − 0.10 ± 0.12; P = 0.453). In five studies, groups exposed to verapamil achieved lower value of glycometabolic outcomes: comparison with values recorded in control groups showed a significant difference, in terms of both HbA1c and plasma glucose levels.
Despite the fact that plasma glucose levels were lowered significantly by verapamil-based treatment in patients with T2D (the HbA1c values were not affected by the drug), the clinical significance of the glycometabolic response induced by verapamil-based treatment remains unclear due to the high variety of sample size and type of studies presently available. Further experimental and clinical trials are needed to clarify unambiguously the role of verapamil in metabolic control.
KeywordsGlycometabolic control HbA1c FPG Diabetes Calcium channel blockers Verapamil
Calcium channel blocker
Fasting plasma glucose
Haemoglobin A1c, A1C, glycosylated haemoglobin, glycated haemoglobin, glycol-haemoglobin
Risk of bias
Type 2 diabetes
Faizan Mazhar is supported by the 33rd cycle Ph.D. programme in “Scienze Farmacologiche Sperimentali e Cliniche”, Università degli Studi di Milano.
CC conceptualised and designed the study, carried out the data extraction and statistical analyses, drafted the manuscript and the summary tables, revised and approved the final manuscript as submitted; AD, GM and FM contributed to literature extraction and manuscript revision and approved the final manuscript as submitted; FD, MP and SR participated in the conceptualisation and design of the study, participated in the analysis of the data, revised the article, and approved the final article as submitted. PF and EC contributed to concept and design of the study, participated in the analysis and interpretation of the data, coordinated and supervised data collection, critically reviewed the manuscript and approved the final manuscript as submitted.
The financial support by the Agenzia Italiana del Farmaco (AIFA), by the Centre of Pharmacovigilance of Regione Lombardia (MEAP project, Monitoraggio degli Eventi Avversi nelle Popolazioni a Rischio, to EC), by the Italian Ministry of Health (Ricerca Corrente 2018, to MP) is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
For this type of study, formal consent is not required.
- 14.Bergantin LB, Jurkiewicz A, García AG, Caricati-Neto A (2015) A calcium paradox in the context of neurotransmission. J Pharm Pharmacol 3:253–261Google Scholar
- 16.Akhtar M, Tchou P, Jazayeri M (1989) Use of calcium channel entry blockers in the treatment of cardiac arrhythmias. Circulation 80(6):IV31-9Google Scholar
- 20.Prospero International Prospective Register of Systematic Reviews. Available from: https://www.crd.york.ac.uk/PROSPERO/. Accessed 2 June 2018
- 23.Higgins JPT, Sterne JAC, Savovic J et al (2016) A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev 10(Suppl 1):29–31Google Scholar
- 24.Andersson DEH, Rojdmark S (1981) Improvement of glucose tolerance by verapamil in patients with non-insulin-dependent diabetes mellitus. Acta Med Scand 210(1–2):27–33Google Scholar
- 25.Chellingsworth MC, Kendall MJ, Wright AD, Singh BM, Pasi J (1989) The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus. J Hum Hypertens 3(1):35–39Google Scholar
- 26.Cortassa G, Borgoglio A, Civelli D et al (1991) Effects of antihypertensive therapy with verapamil on glucose tolerance and insulin secretion in type II diabetics. Curr Ther Rese Clin Exp 49(5):843–853Google Scholar
- 29.Goicolea I, Fernández González R, Piniés J et al (2002) Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study. Nefrologia 22(2):170–178Google Scholar
- 31.Röjdmark S, Andersson DE (1984) Influence of verapamil on glucose tolerance. Acta Med Scand Suppl 681:37–42Google Scholar
- 35.Andersson DE, Röjdmark S, Hed R, Sundblad L (1982) Hypercalcemic and calcium-antagonistic effects on insulin release and oral glucose tolerance in man. Acta Med Scand 211(1–2):35–43Google Scholar